BioInvent International
38.05
SEK
+0.66 %
Less than 1K followers
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
BioInvent International is a biotechnology company focused on the development of innovative antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.
Read moreMarket cap
2.5B SEK
Turnover
3.34M SEK
Revenue
44.69M
EBIT %
-1,054.06 %
P/E
-
Dividend yield-%
-
Financial calendar
26/8
2025
Interim report Q2'25
29/10
2025
Interim report Q3'25
All
Webcasts
Press releases
ShowingAll content types
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025
BioStock: BioInvent fokuserar på första linjens behandling
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools